Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Regeneron Pharmaceuticals
The maximum duration of the study was up to 523 weeks:
* Up to 1-week of screening, if any.
* At least 264 weeks of open label treatment phase and up to 516 weeks as maximum.
* 6-week post-treatment follow-up as required per protocol.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Main study:
Participants with RA who were previously randomized in the sarilumab RA clinical program: e.g., the EFC11072 study, ACT11575 study, EFC10832 study, SFY13370, and EFC13752 study.
Sub-study:
Participants enrolled in the LTS11210 study who were receiving either sarilumab 200mg q2w PFS or sarilumab 150mg q2w PFS and who were able and willing to participate in this sub-study.
Participants who had been enrolled in the main study for at least 24 weeks. Participants must sign a sub-study written informed consent prior to any sub-study related procedure.
You may not be if
Main study:
Participants with any adverse event (AE) led to permanent study drug discontinuation from a prior study.
Participants with an abnormality(ies) or AEs that per investigator judgment would adversely affect participation of the participant in the study.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Clareo Health | Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)
